ArticleJTO clinical and research reports2026
Multi-Institutional Integration of Circulating miRNAs and Protein Tumor Markers for Early Lung Cancer Detection.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early detection of lung cancer is essential for improving survival rates. However, previously reported diagnostic biomarkers based on circulating microRNAs (cfmiRNAs) are often hindered by single-institutional biases and a lack of reproducibility. This study aimed to identify and verify a robust cfmiRNA-based diagnostic signature integrated with protein tumor markers using a large-scale, multi-institutional cohort. Methods: A multi-institutional observational study was conducted across 11 hospitals in Taiwan between 2024 and 2025. Plasma samples were collected from 752 participants, including 255 preoperative patients with lung cancer and 497 healthy controls. To mitigate site-specific effects and confounding factors, candidate cfmiRNAs were identified through stability selection with Monte Carlo sampling. A multiomics classification model was developed by integrating the miRNA panel with established protein markers (CEA, CA19-9, SCC, and Cyfra21-1). Results: A 15-miRNA diagnostic biosignature, functionally linked to tumor progression and cellular stress-related pathways, was identified. The final integrated multiomics model achieved an area under the ROC curve of 84% (95% confidence interval: 76-91) in an independent verification data set. At a fixed specificity of 80%, the cancer detection model reported a sensitivity of 73%. The multi-institutional approach provided a more generalized assessment of biomarker performance than localized cohorts. Conclusions: Our findings demonstrate the potential of multiomics integration in overcoming institution-specific biases and provide the necessary groundwork for lung cancer detection in an Asian population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.